import { StudyStatus } from '../../models/enums';
import { Study } from '../../models/interfaces/study.interface';

export const mockStudies: Study[] = [
  {
    id: '1',
    title:
      'A Randomized, Double-Blind, Placebo-Controlled Study of Drug X in Patients with Advanced Cancer',
    shortTitle: 'STUDY-001',
    protocolNumber: 'PRO-2024-001',
    phase: 'phase_2',
    studyType: 'interventional',
    status: StudyStatus.RECRUITING,
    therapeuticAreas: ['oncology'],
    indication: 'Advanced Solid Tumors',
    sponsorName: 'ABC Pharma Inc.',
    principalInvestigator: 'Dr. Jane Smith',
    plannedStartDate: new Date('2024-03-01'),
    plannedEndDate: new Date('2025-12-31'),
    plannedEnrollment: 120,
    currentEnrollment: 85,
    sites: 5,
    completedSites: 3,
    createdDate: new Date('2024-01-15'),
    lastModified: new Date('2024-02-20'),
    createdBy: 'admin@example.com',
    riskLevel: 'medium',
    budget: 1000000,
    estimatedDuration: 12,
    primaryEndpoint: 'Progression-free survival',
    secondaryEndpoints: ['Overall survival', 'Safety profile'],
    inclusionCriteria: ['Age 18-75', 'Confirmed diagnosis of advanced solid tumor'],
    exclusionCriteria: ['Pregnant or nursing', 'Severe renal impairment'],
  },
  {
    id: '2',
    title: 'Phase III Study Comparing Drug Y vs Standard of Care in Heart Failure Patients',
    shortTitle: 'CARDIO-HF-2024',
    protocolNumber: 'PRO-2024-002',
    phase: 'phase_3',
    studyType: 'interventional',
    status: StudyStatus.ACTIVE,
    therapeuticAreas: ['cardiology'],
    indication: 'Heart Failure',
    sponsorName: 'CardioTech Solutions',
    principalInvestigator: 'Dr. Robert Johnson',
    plannedStartDate: new Date('2024-01-15'),
    plannedEndDate: new Date('2026-06-30'),
    plannedEnrollment: 300,
    currentEnrollment: 245,
    sites: 12,
    completedSites: 8,
    createdDate: new Date('2023-11-10'),
    lastModified: new Date('2024-02-18'),
    createdBy: 'admin@example.com',
    riskLevel: 'high',
    budget: 2500000,
    estimatedDuration: 24,
    primaryEndpoint: 'Cardiovascular death or heart failure hospitalization',
    secondaryEndpoints: ['Quality of life', 'Exercise capacity'],
    inclusionCriteria: ['Age 18+', 'NYHA Class II-IV heart failure'],
    exclusionCriteria: ['Recent MI', 'Severe liver disease'],
  },
  {
    id: '3',
    title: "Observational Study of Biomarkers in Alzheimer's Disease Progression",
    shortTitle: 'NEURO-AD-2024',
    protocolNumber: 'PRO-2024-003',
    phase: 'not_applicable',
    studyType: 'observational',
    status: StudyStatus.PLANNING,
    therapeuticAreas: ['neurology'],
    indication: "Alzheimer's Disease",
    sponsorName: 'NeuroTech Research',
    principalInvestigator: 'Dr. Emily Brown',
    plannedStartDate: new Date('2024-09-01'),
    plannedEndDate: new Date('2027-09-01'),
    plannedEnrollment: 500,
    currentEnrollment: 0,
    sites: 8,
    completedSites: 0,
    createdDate: new Date('2024-08-01'),
    lastModified: new Date('2024-08-15'),
    createdBy: 'researcher@example.com',
    riskLevel: 'low',
    budget: 750000,
    estimatedDuration: 36,
    primaryEndpoint: 'Change in cognitive assessment scores',
    secondaryEndpoints: ['Biomarker progression', 'Brain imaging changes'],
    inclusionCriteria: ['Age 50+', 'Mild cognitive impairment or early dementia'],
    exclusionCriteria: ['Other neurodegenerative diseases', 'Severe depression'],
  },
  {
    id: '4',
    title: 'Phase I Dose Escalation Study of Novel Immunotherapy in Melanoma',
    shortTitle: 'IMMUNO-MEL-001',
    protocolNumber: 'PRO-2024-004',
    phase: 'phase_1',
    studyType: 'interventional',
    status: StudyStatus.RECRUITING,
    therapeuticAreas: ['oncology', 'immunology'],
    indication: 'Advanced Melanoma',
    sponsorName: 'ImmunoTherapeutics Inc.',
    principalInvestigator: 'Dr. Sarah Wilson',
    plannedStartDate: new Date('2024-06-01'),
    plannedEndDate: new Date('2025-12-01'),
    plannedEnrollment: 45,
    currentEnrollment: 12,
    sites: 3,
    completedSites: 1,
    createdDate: new Date('2024-05-01'),
    lastModified: new Date('2024-06-10'),
    createdBy: 'admin@example.com',
    riskLevel: 'high',
    budget: 850000,
    estimatedDuration: 18,
    primaryEndpoint: 'Maximum tolerated dose and dose-limiting toxicities',
    secondaryEndpoints: ['Pharmacokinetics', 'Preliminary efficacy'],
    inclusionCriteria: ['Age 18+', 'Metastatic melanoma', 'ECOG PS 0-1'],
    exclusionCriteria: ['Brain metastases', 'Autoimmune disease'],
  },
  {
    id: '5',
    title: 'Pediatric Study of Safety and Efficacy of Diabetes Drug in Children',
    shortTitle: 'PEDIA-DM-2024',
    protocolNumber: 'PRO-2024-005',
    phase: 'phase_2',
    studyType: 'interventional',
    status: StudyStatus.SUSPENDED,
    therapeuticAreas: ['endocrinology'],
    indication: 'Type 1 Diabetes',
    sponsorName: 'Pediatric Therapeutics',
    principalInvestigator: 'Dr. Michael Chen',
    plannedStartDate: new Date('2024-02-01'),
    plannedEndDate: new Date('2025-08-01'),
    plannedEnrollment: 80,
    currentEnrollment: 35,
    sites: 6,
    completedSites: 2,
    createdDate: new Date('2024-01-01'),
    lastModified: new Date('2024-03-15'),
    createdBy: 'pediatric@example.com',
    riskLevel: 'medium',
    budget: 650000,
    estimatedDuration: 18,
    primaryEndpoint: 'Change in HbA1c from baseline',
    secondaryEndpoints: ['Hypoglycemic events', 'Growth parameters'],
    inclusionCriteria: ['Age 6-17', 'Type 1 diabetes >6 months', 'HbA1c 7.0-11.0%'],
    exclusionCriteria: ['DKA in past 3 months', 'Severe hypoglycemia'],
  },
];
